Clinical trial
Phase I/II Study of hLL1 in Multiple Myeloma
NCT00421525 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00421525 |
|---|---|
| Title | Phase I/II Study of hLL1 in Multiple Myeloma |
| Official title | A Phase I/II Study of Immunotherapy With hLL1 Administered Twice Weekly for 4 Consecutive Weeks in Patients With Multiple Myeloma |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma, Myeloma, Plasma-Cell, PLASMACYTOMA |
| Intervention type | Biological |
| Interventions | milatuzumab |
| Enrollment | 25 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jan 12, 2007 |
| Last update posted | Aug 16, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: